Overview

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

Status:
Completed
Trial end date:
2020-06-23
Target enrollment:
Participant gender:
Summary
The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.
Phase:
Phase 4
Details
Lead Sponsor:
George Sakoulas, MD
Collaborator:
Octapharma
Treatments:
gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin